AGC Biologics Expands Cell Therapy Suites at Longmont ATMP Campus

AGC Biologics, a global biopharmaceutical CDMO, expanded capacity with the addition of three new Grade B cell therapy suites to its Longmont, CO facility. 
 
The new addition at Longmont provides two new Process Suites and one new Flex suite, bringing expanded capabilities to its Colorado site. With more than 30,000 square feet of added space, the new segregated, multiproduct suites feature state-of-art modular clean room design, flexible capacity configuration, and the latest cell therapy equipment for open and closed processes, offering autologous and allogeneic cell therapy manufacturing. 
 
The three new cell therapy suites bring additional capacity for AGC Biologics’ North American hub for cell and gene therapy services with end-to-end cell therapy development and manufacturing services in one location. The new labs extend the capabilities at the site and complement the site’s robust viral vector development and manufacturing services, offering unique benefits to developers looking for one centralized location that can offer a full set of services for bringing their products to market. 
 
Other key features of the site include support for early-stage process development services, commercial manufacturing, quality control and analytics, fill-finish capabilities, and an onsite warehouse. Additionally, the company can add nine additional cell therapy suites to meet market demand.
 
“The new cell therapy suites are a tremendous achievement for this site. We have integrated the latest technology to complete our unique cell therapy services and have created ideal environments for developing these life-changing treatments,” said Whitney Sandberg, General Manager, AGC Biologics Colorado. “This is the final piece for this campus that accompanies our comprehensive viral vector capabilities and gives developers a true end-to-end manufacturing site in North America to support their product’s every need, at any stage.”